Skip To Main Content
MELANIE GERMANO on Muck Rack

MELANIE GERMANO

As seen in: Nature

Get in touch with MELANIE

Contact MELANIE, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial

|
By Fredrik N Albach, Marie Luise Hütter-Krönke, Thanh Le, Thành Lê, Julia M. Giezen, Murat Torgutalp, Arne Sattler, Ioanna Minopoulou, Robert Biesen, Edgar Wiebe, Christian Furth, Jan Zernicke, MELANIE GERMANO, Johan Verhagen, Artur Wilhelm, Maria Dzamukova, Klaus Engel, Simon Schallenberg, Aimo Kannt, Nicole Ziegler, Nadine Unterwalder, Alexander Pfeil, Martin Krusche, Olaf Penack, Tobias Alexander, Werner Stenzel, Manfred Wuhrer, Kamran Movassaghi, Thomas E. Dorner, Eicke Latz, Thomas Vogl, Antonia Busse, Georg Schett, Hans Ulrich Scherer, Rene Toes, René E. M. Toes, Arnd Kleyer, Ulrich Keller, Lars Bullinger, David Simon, Gerhard Krönke, Marie C. Rehm, Vincent Casteleyn, Thorben Witte, Michaela Fehringer, Mark Beling, Elpida Phithak
| Nature Verified
Abstract Chimeric antigen receptor (CAR) T cell-mediated B cell depletion has demonstrated efficacy in several autoimmune diseases. Here we report clinical and molecular data obtained during the nonrandomized phase 1 part of the phase 1/2 COMPARE trial, evaluating safety and efficacy of mivocabtagene autoleucel (miv-cel), an autologous fully human CD19 CAR T cell therapy, in rheumatoid arthritis (RA).
Open in Who Shared Issue with article?
See all 1 articles